UPFIELD
9.1.2024 08:58:37 CET | Business Wire | Press release
Upfield, global leader in plant-based foods, today announces the world's first plastic-free, recyclable tub for its plant butters and spreads.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108563070/en/
Upfield launches world's first plastic-free, recyclable tub for its plant butters and spreads (Photo: Business Wire)
Following four years of innovation, in collaboration with Footprint, MCC and Pagès Group, this introduction marks the beginning of Upfield's transition to a paper solution across its portfolio, delivering on the company's ambition to reduce plastic content by 80% by 2030.
Initially launched in Austria with Flora Plant towards the end of 2023, Upfield expects further scaling of its paper solution, aiming to replace up to two billion plastic tubs by 2030, avoiding more than 25,000 tons of plastic waste per year.
The pioneering paper tubs were developed with Upfield’s leading Research & Development team utilising Footprint's material sciences technology. They are made from compressed wet paper fibres and are waterproof, oil-proof, and recyclable in local paper waste streams. The tub has received Conventional Plastic Free Certification and uses paper from a PEFC-certified supplier. Upfield expects the packaging to achieve home compostability certification by 2025.
David Haines, Group CEO for Upfield, commented, "As a global leader in plant-based foods, we take our responsibility to make a positive impact on the world seriously. Globally, 40% of all plastic produced is for packaging that is used once and then discarded, it is clear that the issue of plastic waste is one of the most critical facing our environment. When we established Upfield, innovating our way out of plastic tubs was our moon-shot and I am very proud of all Upfielders that continue to work towards this goal. Consumers today demand products that benefit both people and the planet. Our plant butters and spreads do exactly that. We're excited about the potential to launch this across our most iconic brands in some of our most important markets."
Unlike many paper packaging solutions, Upfield's paper tubs do not have a plastic liner so they can be recycled along with other paper and cardboard household waste, as verified by a leading European recycling company.
Karina Cerdeira, Head of Packaging for Upfield, said, "We are proud to have created, with Footprint, an innovative paper-based tub that is durable, oil-resistant and appealing and which many thought would be impossible with paper. But after years of dedicated focus from joint Upfield and Footprint R&D teams and dozens of prototypes, we made the impossible, possible. This new paper tub marks a true milestone for sustainable packaging that significantly minimises reliance on plastic. We will continue pushing boundaries through further innovation to adapt for compostability, develop new sizes and formats, and refine towards the optimal solution. We hope what we've achieved inspires other businesses to keep pursuing positive change."
Yoke Chung, Co-founder and Chief Technology & Innovation Officer for Footprint, added, "Footprint's commitment to a more sustainable planet is showcased through our partnership with Upfield. The introduction of a ground-breaking solution, in collaboration with Upfield establishes a pioneering industry standard. This marks the introduction of the first oil-resistant paper tub for plant-based spreads. We are proud to collaborate with Upfield on this transformative endeavour, as it resonates with our shared objective of assisting customers in realizing their sustainability goals. This collaborative effort underscores the transformative influence of innovation in fostering positive environmental change to shape a brighter future for everyone."
To stay up to date on the journey, follow @UpfieldGlobal on social or visit Upfield.com.
About Upfield
Upfield is a global leader in plant-based food, operating in four categories – butters and spreads, creams, liquids and cheeses. Over the last four years, Upfield has been on a journey to separate, stabilise, transform, and turn around our platform which today is unique in the plant-based space – combining scale of historical reach and scale of future growth ambition. We are built on the foundation of our power brands, which achieve high Brand Power Index versus wider consumer goods brands in all our key markets. Our brands are built upon our heritage of 150 years of knowledge of plant-based foods, deep R&D expertise, with 15 manufacturing sites across five continents and an end-to-end supply chain ensuring best service and delivery for our customers and consumers. Upfield's processes, products and people combine to create a business where our portfolio and purpose are completely aligned. www.upfield.com
About Footprint
Footprint is a global materials science and technology company with a clear vision to create a healthier planet and healthier people. Our mission is to provide solutions to eliminate single-use plastics in our food chain. Footprint's engineers use plant-based fiber technology to design, develop, and manufacture bio-based products. Footprint is rapidly expanding into new categories with customized and patented solutions for customers. While working with leading global consumer brands, Footprint's products have already led to a worldwide reduction of millions of pounds of plastic waste from entering the environment.
Footprint was founded in 2014 and employs approximately 2,000 people with operations in the U.S., Mexico, Europe, and Asia. Footprint was named to Fast Company's “Brands that Matter” list in 2022, CNBC’s “Disruptor 50” list in 2021, and Fortune’s “Change the World” list in 2020.
For more information on Footprint’s sustainable solutions, visit www.footprintus.com.
MCC Labels provides the label for the paper tub and Pagès the equipment (robot system) to apply the label.
About MCC Verstraete
MCC Verstraete has over 30 years of experience in offset-printing labels for injection molding, blow molding and thermoforming. In-depth understanding of materials, innovation and sustainability have made MCC Verstraete a world leader, producing over 60 million in mold labels every single day for numerous segments within the packaging industry. The drive for innovation recently led to 2 new product categories: next to polypropylene in mold labels, MCC Verstraete offers Molded Fiber Labeling™ and PP heat-seal die-cut lidding. MCC Verstraete has production sites in Belgium, Australia and the US. Together with MCC Korsini (Turkey) and Karydakis IML SA (Greece), MCC Verstraete forms the IML Business Unit within Multi-Color Corporation.
Visit iml.mcclabel.com/en for more information.
About Pagès Group
Pagès Group is a worldwide company with more than 40 years of expertise in decoration solutions and downstream automation for the packaging industry. The group has subsidiaries in France, in the Netherlands, the USA, Canada and China. As of today, more than 3000 automation systems have been installed in more than 45 countries. Among others, we developed Molded Fiber Labeling (MFL™), a world premiere decoration technology to decorate fiber molded containers for a sustainable and stunning packaging. To learn more about Pagès Group automation solutions, please visit www.pagesgroup.net or follow us on LinkedIn.
About EMSUR
EMSUR is the business unit of Grupo Lantero that provides flexible packaging solutions mainly for the food and beverage sector, home and personal care products, with lamination and printing in both rotogravure and flexography.
It currently has production sites in Europe and America, which allows to develop its activity in more than 80 countries across America, Europe, Africa and Asia. Emsur produces almost 600 million square metres of sleeves, lids, banners, labels, die-cuts, pouches and other flexible products per year.
Innovation, developed through the Innotech team and facilities, is one of their key pillars. Visit www.emsur.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108563070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
